Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151.
In development [GID-IP1046] Expected publication date: TBC
In development [GID-IPG10171] Expected publication date: TBC
In development [GID-IPG10172] Expected publication date: TBC
In development [GID-IPG10067] Expected publication date: TBC
In development [GID-IPG10137] Expected publication date: 27 January 2021
In development [GID-IPG10154] Expected publication date: TBC
In development [GID-IP1180] Expected publication date: TBC